CASTLE BIOSCIENCES INC (CSTL) Stock News
NASDAQ:CSTL - Nasdaq - US14843C1053 - Common Stock - Currency: USD
CSTL Latest News, Press Relases and Analysis
New Data at AACR Annual Meeting Highlights Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Distant Metastasis
Castle Biosciences will share new data intended to improve the care of patients with cutaneous and uveal melanoma at the AACR Annual Meeting 2025....
New Data at AACR Annual Meeting Highlights Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Distant Metastasis
Castle Biosciences to Release First Quarter 2025 Financial Results and Host Conference Call on Monday, May 5, 2025
Castle will release its financial results for the first quarter ended March 31, 2025, after the close of market on Monday, May 5, 2025....
Castle Biosciences to Release First Quarter 2025 Financial Results and Host Conference Call on Monday, May 5, 2025
Castle Biosciences Strengthens Commitment to Esophageal Cancer Awareness Through Collaborative Partnerships
Castle is supporting key educational programs and initiatives throughout April in recognition of Esophageal Cancer Awareness Month....
Castle Biosciences Strengthens Commitment to Esophageal Cancer Awareness Through Collaborative Partnerships
Castle Biosciences Honored with a Top Workplaces USA Award for Fourth Consecutive Year
Castle announces 4th Top Workplaces USA win, ranking 30th of 358 U.S. companies with 500-999 employees...
Castle Biosciences Honored with a Top Workplaces USA Award for Fourth Consecutive Year
Guardant Health Stock Sees RS Rating Jump To 83
On Wednesday, Guardant Health stock got a positive adjustment to its Relative Strength (RS) Rating, from 75 to 83.
Publication of Data from Prospective, Multicenter Study Demonstrates Positive Survival Outcomes in Patients with Low-Risk Melanoma Who Avoided Sentinel Lymph Node Biopsy with Information from Castle Biosciences’ DecisionDx®-Melanoma Test
Castle announced the recent publication of prospective data demonstrating the significant impact of DecisionDx-Melanoma on SLNB decision-making....
Castle Biosciences to Present New Data at EADO Supporting the Clinical Value of the DecisionDx®-Melanoma Test in Guiding Risk-Aligned Management of Patients with Melanoma
Castle will present data on DecisionDx-Melanoma at the 11th World Congress of Melanoma and 21st European Association of Dermato-Oncology (EADO) Congress....
Castle Biosciences' DecisionDx®-SCC Data Earns Top Five Abstract at NCCN 2025, Shows Significantly Enhanced Risk Stratification Beyond Current Staging Within NCCN Risk Groups
Castle Biosciences will share new data on DecisionDx-SCC and DecisionDx-Melanoma at the NCCN 2025 Annual Conference....
Castle Biosciences Reports Fourth Quarter and Full-Year 2024 Results
Castle Biosciences to Participate in Upcoming Investor Conferences
Castle Biosciences to Release Fourth Quarter and Full-Year 2024 Financial Results and Host Conference Call on Thursday, Feb. 27, 2025
Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Results
Castle Biosciences Announces New York State Department of Health Approval of Its TissueCypher® Barrett’s Esophagus Test
Castle Biosciences Highlights Progress for its Pipeline Atopic Dermatitis Gene Expression Profile Test
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Castle Biosciences to Present at the Piper Sandler 36th Annual Healthcare Conference
Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fourth Consecutive Year
Castle Biosciences Surpasses 25,000 Test Reports Delivered for its TissueCypher® Barrett’s Esophagus Test
